GleamWall
中文EN

AZR Azora Therapeutics, Inc. (DE)

Pharmaceutical Preparations · Nasdaq · SEC CIK 1513525 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1,397.4%
TTM EPS YoY76.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-855.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets22.4%
Debt / equity—
Current ratio4.43x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.13x
Accruals ratio-742.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$2.62M$3.23M
SG&A expense$5.18M$5.06M
Operating income-$7.80M-$8.28M
Pretax income-$7.98M-$13.20M
Net income-$7.98M-$13.20M
EPS (basic)-11.93-68.01
EPS (diluted)-11.93-68.01
Weighted avg. shares (diluted)668,630194,059
Balance sheet
Cash & equivalents$5.88M$3.75M
Current assets$6.18M$4.06M
Intangibles$3,000$3,348
Total assets$6.67M$5.04M
Current liabilities$1.40M$975,858
Total liabilities$1.40M$975,858
Shareholders' equity$5.28M$4.07M
Shares outstanding1.11M258,826
Cash flow statement
Operating cash flow-$6.49M-$6.92M
Investing cash flow$150,000—
Financing cash flow$8.47M$7.85M
Stock-based compensation$676,200$796,831

Free plan shows the latest 2 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.